KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Assets (2023 - 2025)

Biocryst Pharmaceuticals' Current Assets history spans 9 years, with the latest figure at $404.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 4.18% year-over-year to $404.3 million; the TTM value through Dec 2025 reached $404.3 million, down 4.18%, while the annual FY2025 figure was $404.3 million, 4.18% down from the prior year.
  • Current Assets reached $404.3 million in Q4 2025 per BCRX's latest filing, up from $355.7 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $511.1 million in Q2 2023 to a low of $355.7 million in Q3 2025.
  • Average Current Assets over 3 years is $435.7 million, with a median of $424.5 million recorded in 2024.
  • Peak YoY movement for Current Assets: dropped 28.88% in 2024, then increased 9.63% in 2025.
  • A 3-year view of Current Assets shows it stood at $496.0 million in 2023, then decreased by 14.92% to $422.0 million in 2024, then decreased by 4.18% to $404.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Current Assets are $404.3 million (Q4 2025), $355.7 million (Q3 2025), and $398.5 million (Q2 2025).